"To meet the new health-care challenges of the 21st century,
some European countries are trying to develop more effective policies to reward innovation and provide patients with innovative biopharmaceuticals while managing national budgets. Health technology assessment is an important tool to evaluate these new therapies from a societal perspective, but crucial differences in processes and methods across the member states is delaying access throughout the EU."

Objective1:Describe European policy to ensure equal and timely access to innovative therapies.

Objective2:Discuss best practices in patient access policies.

Objective3:Define the role of the biopharmaceutical industry that favors the establishment of a patient-driven political agenda.